ZA202203730B - Lassavirus vaccines - Google Patents

Lassavirus vaccines

Info

Publication number
ZA202203730B
ZA202203730B ZA2022/03730A ZA202203730A ZA202203730B ZA 202203730 B ZA202203730 B ZA 202203730B ZA 2022/03730 A ZA2022/03730 A ZA 2022/03730A ZA 202203730 A ZA202203730 A ZA 202203730A ZA 202203730 B ZA202203730 B ZA 202203730B
Authority
ZA
South Africa
Prior art keywords
protein
flavivirus
sequence
terminally
signal peptide
Prior art date
Application number
ZA2022/03730A
Other languages
English (en)
Inventor
Kai Dallmeier
Viktor Lemmens
Johan Neyts
Felipe Lorena Sanchez
Original Assignee
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath filed Critical Univ Leuven Kath
Publication of ZA202203730B publication Critical patent/ZA202203730B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2022/03730A 2019-09-13 2022-03-31 Lassavirus vaccines ZA202203730B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19197202 2019-09-13
PCT/EP2020/075541 WO2021048402A1 (en) 2019-09-13 2020-09-11 Lassavirus vaccines

Publications (1)

Publication Number Publication Date
ZA202203730B true ZA202203730B (en) 2025-09-25

Family

ID=68137784

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/03730A ZA202203730B (en) 2019-09-13 2022-03-31 Lassavirus vaccines

Country Status (8)

Country Link
US (1) US12558410B2 (https=)
EP (1) EP4041300A1 (https=)
JP (1) JP7663250B2 (https=)
CN (1) CN114728054A (https=)
AU (1) AU2020346382A1 (https=)
BR (1) BR112022004378A2 (https=)
WO (1) WO2021048402A1 (https=)
ZA (1) ZA202203730B (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042014A1 (en) 2003-10-29 2005-05-12 The University Of Queensland West nile virus vaccine
JP5779352B2 (ja) * 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
GB201307528D0 (en) 2013-04-26 2013-06-12 Univ Leuven Kath Bacterial artificial chromosomes
BR102016018430A2 (pt) * 2016-08-10 2018-02-27 Fundação Oswaldo Cruz Cassete de expressão heteróloga, constructo de dna e composição vacinal para imunizar contra flavivírus e/ou outros patógenos.
WO2019018501A1 (en) 2017-07-18 2019-01-24 Geovax Inc. COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE

Also Published As

Publication number Publication date
BR112022004378A2 (pt) 2022-06-07
EP4041300A1 (en) 2022-08-17
CN114728054A (zh) 2022-07-08
US20220378903A1 (en) 2022-12-01
JP2022547695A (ja) 2022-11-15
US12558410B2 (en) 2026-02-24
JP7663250B2 (ja) 2025-04-16
AU2020346382A1 (en) 2022-04-21
WO2021048402A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
Trent et al. Partial nucleotide sequence of St. Louis encephalitis virus RNA: structural proteins, NS1, ns2a, and ns2b
Rochman et al. Molecular adaptations during viral epidemics
HUP0002139A2 (hu) Kiméra flavivírus-vakcinák
UA98620C2 (uk) Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2
GR3032416T3 (en) Chimeric and/or growth-restricted flaviviruses.
EP3191589B1 (en) Flavivirus virus like particle
JP2016521553A5 (https=)
JP2011523347A5 (https=)
CA3099330A1 (en) Synthetic chimeric vaccinia virus
WO2011153351A3 (en) Novel modified live-attenuated vaccines (mlv) and subunit vaccines created by dna shuffling against porcine reproductive and respiratory syndrome virus (prrsv)
Maruggi et al. Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity
CA2914550C (en) Avian cells for improved virus production
WO2023056351A8 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
CN103352029A (zh) 一种乙脑/森林脑炎嵌合病毒及其应用
MX390966B (es) Vacunas contra el dengue
ZA202203730B (en) Lassavirus vaccines
WO2011038473A8 (pt) Método, kit, plasmídeo e composição para induzir resposta imune contra virus da dengue baseado em vacinas de dna e vírus quiméricos
MX2022004220A (es) Composición inmunogénica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteina spike del sars-cov-2.
MX2021001901A (es) Nucleotidos de codificacion del factor ix.
JP2011523642A5 (https=)
Morrison et al. Abrogation of TLR3 inhibition by discrete amino acid changes in the C-terminal half of the West Nile virus NS1 protein
ZA202203731B (en) Chimeric filovirus vaccines
JP2006526393A5 (https=)
IL315248A (en) A viral vector genome encoding an insulin fusion protein
EP4265631A3 (en) Live-attenuated flaviruses with heterologous antigens